Discovery reveals how acetylation controls key enzyme linked to cancer growth

Researchers from the University of Seville have participated in research to identify the molecular details of the regulation ...

Williams-Beuren syndrome: Early enzyme changes may hold key to future treatments

Williams-Beuren syndrome is a rare, congenital disease in which the main morbidity and mortality comes from obstructions, or ...

Agios Pharmaceuticals, Inc. (AGIO): A bull case theory

We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AGIO. Agios Pharmaceuticals, Inc.’s share was ...

Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline

Agios Pharmaceuticals (NASDAQ:AGIO) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...

Agios Pharma Sets 2026 Strategic Priorities After AQVESME Approval

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.
Rutland Herald

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...
clinicaladvisor.com

Aqvesme Approved for Anemia in Alpha- or Beta-Thalassemia

Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...
U.S. News & World Report

Agios Pharma Shares Jump as US FDA Expands Approval for Blood Disorder Drug

Dec 24 (Reuters) - Shares of Agios ‌Pharmaceuticals jumped nearly 16% on Wednesday ‌after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of ...